{"result": "(\"entity\"<|>INMUNONUTRICIÓN<|>EVENT<|>Inmunonutrición refers to the use of specialized nutritional formulas aimed at enhancing the immune response in patients, particularly in clinical settings.)\n##\n(\"entity\"<|>HOSPITALIZACIÓN<|>EVENT<|>Hospitalización refers to the process of admitting patients to a hospital for medical treatment, which may involve the use of specialized nutritional support.)\n##\n(\"entity\"<|>DISTRÉS RESPIRATORIO<|>EVENT<|>Distrés respiratorio is a medical condition characterized by difficulty in breathing, which may be influenced by nutritional support interventions.)\n##\n(\"entity\"<|>ABSCESO INTRAABDOMINAL<|>EVENT<|>Absceso intraabdominal is a medical condition involving a collection of pus within the abdominal cavity, which may be affected by nutritional status.)\n##\n(\"entity\"<|>COMPLICACIONES SÉPTICAS<|>EVENT<|>Complicaciones sépticas refer to septic complications that can arise in patients, potentially influenced by their nutritional support and overall health.)\n##\n(\"relationship\"<|>INMUNONUTRICIÓN<|>HOSPITALIZACIÓN<|>Inmunonutrición is often utilized during hospitalización to improve patient outcomes and support recovery<|>8)\n##\n(\"relationship\"<|>INMUNONUTRICIÓN<|>DISTRÉS RESPIRATORIO<|>Inmunonutrición may help reduce the incidence of distrés respiratorio in patients<|>6)\n##\n(\"relationship\"<|>INMUNONUTRICIÓN<|>ABSCESO INTRAABDOMINAL<|>Inmunonutrición can potentially lower the risk of absceso intraabdominal in patients<|>6)\n##\n(\"relationship\"<|>INMUNONUTRICIÓN<|>COMPLICACIONES SÉPTICAS<|>Inmunonutrición aims to decrease the rate of complicaciones sépticas in patients<|>6)\n<|COMPLETE|>", "input": "MANY entities and relationships were missed in the last extraction. Remember to ONLY emit entities that match any of the previously extracted types. Add them below using the same format:\n", "parameters": {"model": "gpt-4o-mini", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": [{"role": "user", "content": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: % péptido | 1,5 53% MCT | 16,4 | 480 | 0,15 4,23 | 0,45 | 1,42 |\n| Impact enteral | 1 | 5,6 | 2,8 27% MCT | 13,4 | 477-519 | 0,34 0,7 | 1,25 | - |\n| Impact oral | 1 | 7,6 | 3,9 28,2% | 18,9 | 690 | 0,67 0,91 | 1,8 | - |\n| Oxepa | 1,5 | 6,3 | 9,4 25% MCT | 10,6 | 384 | 0,94 1,85 | - | - |\n| Perative | 1,3 | 6,7 | 3,7 40% MCT | 17,7 | 308 | 0,16 4,8 | 0,85 | - |\n| Prosure | 1,23 | 5,4 | 2,7 16,2% MCT | 14,9 | 474 | 1,75 0,27 | - | - |\n| Forticare | 1,6 | 9 | 5,3 | 19,1 | 730 | 2,7 1,2 | - | - |\n| Cubison | 1 | 5,5 | 3,3 | 12,5 | 315 | 1,41 5 | 0,625 | - |\n| Resource support | 1,55 | 9 | 5,3 9,4% | 17,9 | 564 | 1,05 1,1 | - | - |\n| Clinutren Repair | 1,25 | 9,3 | 2,8 | 15,6 | 580 | 1,07 7,2 | 0,47 | |\n| Suportan drink | 1,5 | 10 | 6,7 | 12,4 | 435 | 0,71 - | - | - |\n| Atempero | 1,51 | 8,3 | 5 | 17,3 | 366 | 0,77 0,9 | - | - |\n\n### Tabla 3. Módulos de glutamina.\n\n| 100 g | Glutamina Vegenat Med® sobre 5 g | Resource Glutamina sobre 5 g | Glutamina NM sobre 10 g | Glutamina NM vial 5 g/40 ml | Kabi Glutamina sobre 20 g | Glutamine sobre 10 g |\n|-------|----------------------------------|------------------------------|-------------------------|-----------------------------|--------------------------|-----------------------|\n| Kcal | 400 | 400 | 399,5 | 399,5 | 375 | 370 |\n| Proteínas g | 100 | 100 | 99,7 | 99,7 | 50 | 120 |\n| L glutamina g | 100 | 100 | 99,7 | 99,7 | 100 | 100 |\n| HC g | 0 | 0 | 0,1 | 0 | 40 | 0 |\n| Lípidos | 0 | 0 | 0,09 | 0 | 0 | 0 |\n\nHC: hidratos de carbono.\n\nen la UCI y también en la hospitalización en planta, generando por tanto un importante ahorro económico. Otro trabajo realizado con la misma fórmula inmunomoduladora anterior fue el de Moore et al.15. En este trabajo multicéntrico se detectaron menos complicaciones sépticas globales (22% frente a 43%). En el grupo con inmunonutrición no hay pacientes con distrés respiratorio, frente al 11% en el grupo control, ni tampoco existen pacientes con absceso intraabdominal.\n\nPosteriormente apareció el trabajo de Mendez16, con unos resultados negativos en el grupo de inmunonutrición, con mayor incidencia de neumonía (72% frente\n---\nTema 50. Inmunonutrición en el soporte nutricional artificial 793\n\nTabla 4. Módulos de arginina.\n\n| 100 g | Arginina Vegenat Med sobre 7 g | Resource Arginaid sobre 7 g | Arginina NM vial 5 g/20 ml | Arginina Nutricia bote 100 g |\n|-------|--------------------------------|-----------------------------|-----------------------------|------------------------------|\n| Kcal | 286 | 238 | 400 | 359 |\n| Prot g | 71,4 | 71 | 99 | 100 |\n| L arginina g | 71,4 | 71 | 99 | 100 |\n| HC g | 0 | 3,6 | 0 | 0 |\n| Lípidos | 0 | 0 | 0 | 0 |\n\na 52%); sin embargo, los grupos no son totalmente equiparables en un inicio (mayor proporción de distrés respiratorio en el grupo de inmunonutrición). Estos resultados fueron parcialmente repetidos por Weimann et al.17, detectando una mayor incidencia de neumonía en el grupo con inmunonutrición (63% frente a 46%),\n######################\nOutput:"}, {"role": "assistant", "content": "(\"entity\"<|>IMPACT ENTERAL<|>ORGANIZATION<|>Impact Enteral is a nutritional product designed for enteral feeding, providing essential nutrients for patients in need of dietary support.)\n##\n(\"entity\"<|>IMPACT ORAL<|>ORGANIZATION<|>Impact Oral is a nutritional product formulated for oral consumption, aimed at providing necessary nutrients for individuals unable to meet their dietary needs through regular food intake.)\n##\n(\"entity\"<|>OXEPA<|>ORGANIZATION<|>Oxepa is a specialized nutritional product that contains a high concentration of MCTs, designed to support patients with specific dietary requirements.)\n##\n(\"entity\"<|>PERATIVE<|>ORGANIZATION<|>Perative is a nutritional product that offers a blend of essential nutrients, particularly for patients requiring specialized dietary support.)\n##\n(\"entity\"<|>PROSURE<|>ORGANIZATION<|>Prosure is a nutritional supplement designed to provide high-quality protein and calories for patients needing additional dietary support.)\n##\n(\"entity\"<|>FORTICARE<|>ORGANIZATION<|>Forticare is a nutritional product that provides a balanced mix of nutrients, aimed at supporting patients with increased nutritional needs.)\n##\n(\"entity\"<|>CUBISON<|>ORGANIZATION<|>Cubison is a nutritional product that offers a specific formulation to meet the dietary needs of patients requiring nutritional support.)\n##\n(\"entity\"<|>RESOURCE SUPPORT<|>ORGANIZATION<|>Resource Support is a nutritional product designed to provide essential nutrients for patients in need of dietary assistance.)\n##\n(\"entity\"<|>CLINUTREN REPAIR<|>ORGANIZATION<|>Clinutren Repair is a specialized nutritional product aimed at supporting recovery and healing in patients with specific dietary needs.)\n##\n(\"entity\"<|>SUPORTAN DRINK<|>ORGANIZATION<|>Suportan Drink is a nutritional beverage formulated to provide essential nutrients for individuals requiring dietary support.)\n##\n(\"entity\"<|>ATEMPERO<|>ORGANIZATION<|>Atempero is a nutritional product designed to meet the dietary needs of patients, particularly in clinical settings.)\n##\n(\"entity\"<|>GLUTAMINA VEGANAT MED<|>ORGANIZATION<|>Glutamina Vegenat Med is a nutritional supplement that provides glutamine, aimed at supporting patients' dietary needs.)\n##\n(\"entity\"<|>RESOURCE GLUTAMINA<|>ORGANIZATION<|>Resource Glutamina is a dietary supplement that offers glutamine to support patients' nutritional requirements.)\n##\n(\"entity\"<|>GLUTAMINA NM<|>ORGANIZATION<|>Glutamina NM is a nutritional product providing glutamine, aimed at patients needing specific dietary support.)\n##\n(\"entity\"<|>KABI GLUTAMINA<|>ORGANIZATION<|>Kabi Glutamina is a specialized nutritional product that offers glutamine for patients requiring dietary assistance.)\n##\n(\"entity\"<|>GLUTAMINE<|>ORGANIZATION<|>Glutamine is a dietary supplement providing glutamine to support patients' nutritional needs.)\n##\n(\"entity\"<|>MOORE ET AL.<|>PERSON<|>Moore et al. is a reference to a group of researchers who conducted a multicenter study on immunonutrition and its effects on patient outcomes.)\n##\n(\"entity\"<|>MENDEZ<|>PERSON<|>Mendez is a researcher who conducted a study on immunonutrition, reporting negative results in a specific patient group.)\n##\n(\"entity\"<|>WEIMANN ET AL.<|>PERSON<|>Weimann et al. is a reference to a group of researchers who studied the effects of immunonutrition on patient outcomes, noting increased incidence of pneumonia.)\n##\n(\"relationship\"<|>MOORE ET AL.<|>IMPACT ENTERAL<|>Moore et al. conducted a study that included the use of Impact Enteral in their research on immunonutrition<|>7)\n##\n(\"relationship\"<|>MENDEZ<|>IMPACT ENTERAL<|>Mendez's study involved the use of Impact Enteral, which was part of the immunonutrition research<|>7)\n##\n(\"relationship\"<|>WEIMANN ET AL.<|>IMPACT ENTERAL<|>Weimann et al. referenced the use of Impact Enteral in their findings related to immunonutrition<|>7)\n##\n(\"relationship\"<|>MOORE ET AL.<|>PROSURE<|>Moore et al. included Prosure in their study on immunonutrition and its effects on patient outcomes<|>7)\n##\n(\"relationship\"<|>MENDEZ<|>PROSURE<|>Mendez's research involved Prosure as part of the immunonutrition study<|>7)\n##\n(\"relationship\"<|>WEIMANN ET AL.<|>PROSURE<|>Weimann et al. referenced Prosure in their findings related to immunonutrition<|>7)\n##\n(\"relationship\"<|>MOORE ET AL.<|>GLUTAMINA VEGANAT MED<|>Moore et al. studied the effects of glutamine products, including Glutamina Vegenat Med, in their research<|>7)\n##\n(\"relationship\"<|>MENDEZ<|>GLUTAMINA VEGANAT MED<|>Mendez's study included Glutamina Vegenat Med as part of the immunonutrition research<|>7)\n##\n(\"relationship\"<|>WEIMANN ET AL.<|>GLUTAMINA VEGANAT MED<|>Weimann et al. referenced Glutamina Vegenat Med in their findings related to immunonutrition<|>7)\n<|COMPLETE|>"}]}